Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Affymetrix, Inc.
The dermatology specialist said a BLA for the IL-13 blocker has been accepted by the US FDA for the treatment of atopic dermatitis.
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.
- Other Names / Subsidiaries
- eBioscience Holding Company, Inc.
- Eureka Genomics